Glenmark Launches FabiFlu For COVID-19 Treatment

Glenmark launches Covid-19 drug FabiFlu, priced at Rs 103 per tablet

The drug has been approved under emergency category and needs an undertaking from the patient.

Fabiflu to be used for patients with mild and moderate symptoms

Glenmark Pharmaceuticals Limited has announced the introduction of Favipiravir under the brand name FabiFlu in tablet form for the treatment of mild & moderate coronavirus (COVID-19) cases in India.

Nearly 80% of all COVID-19 positive cases in India are under this category. FabiFlu is India’s first oral antiviral drug for treatment of mild & moderate COVID-19 patients, the company said.

FabiFlu is the first oral Favipiravir-approved medication for the treatment of COVID-19, the company said in a statement.

The drug will be available as a 200 mg tablet at a maximum retail price (MRP)of Rs 3,500 for a strip of 34 tablets, Glenmark Pharmaceuticals said.

FabiFlu is the first oral favipiravir-approved medication in India for the treatment of COVID-19, it said in a statement.

Here’s all you need to know about FabiFlu:

* The medicine has produced up to 88% improvement in mild to moderate coronavirus patients during clinical trials, making it the first oral antiviral drug available under emergency use authorization to treat Covid-19 patients in India.

*It is not an over-the-counter drug, and its sale will only be allowed on possession of a valid medical prescription by a doctor.

* It will be sold in a pack of 34 oral tablets of 200 mg each at a cost of  Rs 3,500 and the cost of the 14-day treatment will be an estimated Rs 14,000.

* Each tablet of 200 mg will costs Rs103

* The dosage will be 3,600 mg on day one, and 1,600 mg from day two onwards for a maximum duration of 14 days.

* Every patient must give his or her informed consent before starting treatment with the drug.

* The medicine can be administered to coronavirus patients between the age group of 18 and 75.